Lv3
230 积分 2022-05-17 加入
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
1个月前
已完结
Extramedullary Plasmacytoma of the Small Intestine: A Case Report
1个月前
已关闭
A striking response to bortezomib in a patient with pleural localization of multiple myeloma
1个月前
已完结
Use of intrapleural bortezomib in myelomatous pleural effusion
1个月前
已完结
Anaplastic variant of plasma cell myeloma with Dutcher bodies
1个月前
已完结
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
2个月前
已完结
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
2个月前
已完结
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
2个月前
已完结
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
2个月前
已完结
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
2个月前
已完结
皖公网安备34019202002308
